Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations.

about

Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations.

Item

http://www.wikidata.org/entity/Q54981628

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Clinical Characteristics and S ...... tor Receptor Double Mutations.

@en

Clinical Characteristics and S ...... tor Receptor Double Mutations.

@nl

type

Item

label

Clinical Characteristics and S ...... tor Receptor Double Mutations.

@en

Clinical Characteristics and S ...... tor Receptor Double Mutations.

@nl

prefLabel

Clinical Characteristics and S ...... tor Receptor Double Mutations.

@en

Clinical Characteristics and S ...... tor Receptor Double Mutations.

@nl

P1476

Clinical Characteristics and S ...... ctor Receptor Double Mutations

@en

P2093

Gui Fang Yang

http://www.w3.org/2001/XMLSchema#string

Hua Li Liu

http://www.w3.org/2001/XMLSchema#string

Min Peng

http://www.w3.org/2001/XMLSchema#string

Yi Yao

http://www.w3.org/2001/XMLSchema#string

P2860

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Mechanism for activation of mutated epidermal growth factor receptors in lung cancer

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Global cancer statistics, 2012

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Clonal evolution in cancer

Screening for epidermal growth factor receptor mutations in lung cancer

P304

7181368

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2018/7181368

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

2018

http://www.w3.org/2001/XMLSchema#string

P50

Yi Ming Weng

Guang Han

Qi Bin Song

P577

2018-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29581983

http://www.w3.org/2001/XMLSchema#string

P932

5822926

http://www.w3.org/2001/XMLSchema#string